Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy

Cyclin-dependent kinase 9 (CDK9) plays a vital role in transcription through regulation of short-lived anti-apoptotic genes required for cancer cell survival. Therefore, targeting CDK9 with small molecule inhibitors has emerged as a potential cancer therapy. This article reviews the most recent CDK9 patent literature (2012-2020) related to small molecule inhibitors in cancer along with their selectivity profile and biological results in preclinical studies.

Automated summary

CDK9 plays a crucial role in cancer cell survival by regulating the transcription of short-lived anti-apoptotic genes. Targeting CDK9 with small molecule inhibitors has emerged as a potential cancer therapy strategy. This article reviews recent CDK9 patent literature related to small molecule inhibitors in cancer and their effectiveness in preclinical studies.